Hosted on MSN9mon
Cabaletta Bio slips after early data for lead assetThe RESET-Myositis and RESET-SLE trials were designed ... representing a May 28 data cut from two patients with immune-mediated necrotizing myopathy and SLE, indicated a well-tolerated safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback